Improving the Lung Cancer Clinical Trial Development by Incorporating Competing Risk Factors

Table 2

Treatment-related adverse events (grade 3-5) and adverse events of respiratory (any grades).

	Immunotherapy ()				Chemotherapy ()
	Pembrolizumab ()	Camrelizumab ()	Atezolizumab ()	Nivolumab ()
Grade 3-5 adverse event occurred
White blood cell count decreased	0	3 (13%)	0	1 (5%)	13 (29%)
Anemia	0	3 (13%)	1 (5%)	0	1 (2%)
Platelet count decreased	0	3 (13%)	1 (5%)	0
Neutropenia	0	2 (8%)	1 (5%)	0	8 (18%)
Hyperglycemia	0	1 (4%)	0	0	0
Leucoderma	0	1 (4%)	0	0	0
Hemoptysis	0	1 (4%)	1 (5%)	0	0
Neutrophil count	0	1 (4%)	0	0	14 (31%)
Pneumonia	0	1 (4%)	0	0	0
GGTP rise	1 (8%)	0	0	0	0
Pancreatitis	1 (8%)	0	1 (5%)	0	0
Serum amylase increased	0	0	1 (5%)	0	0
Erythra	0	0	1 (5%)	0	0
Hyponatremia	0	0	1 (5%)	0	0
Bone pain	0	0	1 (5%)	1	0
Myelodysplastic syndrome	0	0	1 (5%)	0	0
Lymphocyte count decreased	0	0	0	1	3 (7%)
Fatigue	0	0	0	1	1 (2%)
Leukopenia	0	0	0	0	5 (11%)
Cough	0	0	0	0	1 (2%)
Abducens nerve disorder	0	0	0	0	2 (4%)
Intestinal obstruction	0	0	0	0	1 (2%)
Zoster	0	0	0	0	1 (2%)
Adverse events of respiratory (any grades)
Pneumonia	2(17%)	2(9%)	1(5%)	2(11%)	2(4%)
Cough	10(83%)	9(39%)	11(58%)	7(37%)	23(51%)
Dyspnea	0	11(4%)	3(16%)	1(5%)	9(20%)
Fever	0	0	2(11%)	0	0